Homepage / Investment / In high-stakes votes, FDA advisors say evidence doesn't back Philip Morris' claims
test Users535352253 Due Diligence Blog Digital Data Rooms for the Netherlands Board Room Apps Secure Board Management With Secure Board Portals What Happens at Board of Directors Meetings? Board Room Software Review How to Prepare Board Rooms for Effective Board Meetings Board Room Software Boosts Performance and Communication Selecting a Secure Data Room Review Local Data Room Service Review How to Find the Best Virtual Data Room Review What to Look for in a Data Room uk Provider Document Storage and Distribution Software Everything About VDRs Corporate Software Advantages How to Choose a Virtual Data Room Provider The Most Secure Way to Transfer Files How to Manage Online Board Meetings Benefits Virtual Data Room Solutions – Must-Haves for M&A and Due Diligence Best Data Room Functions for the Different Types of Industries How to Choose a VDR Software Provider How to Choose an Online Board Portal The Benefits of a Boardroom Review Board Room Online Solutions – How to Get the Most Out of Your Board Meetings Why You Need a Board Room How a Board Room Blog Can Transform Your Business Choosing the Best Board Room Format How to Have Productive and Engaging Board Directors Meetings Choosing the Right Virtual Data Room How to Keep Safe Documents Storage Teaching Kids About Online Safety Avoid Costly Mistakes With Free Data Room Services Corporate Virtual Data Secure Online Data Rooms Solutions How to Keep Share, Edit and Delete Your Data Safe Virtual Data Room Software Secrets for M&A Due Diligence What to Look For in Boardroom Providers Board of Directors Blog Posts How to Deliver Value at Your Board Meetings How to Have Effective Board Meetings Responsibilities of Board Members Deal Management – How to Effectively Manage a Complex Sales Pipeline Data Rooms For Mergers And Acquisitions How to Have a Successful Board Room Meeting Choosing a Board Room Service Provider What is a Board Room Service? Board Room Software Review – Choosing the Best Portal for Mother Board Meetings Why a Board Room Providers Review Is Important What Is a Board Room Review? Venture Software for VC Firms What Is an Assessment Report? The Importance of a Tech Audit Popular Business Applications What to Look For in a Data Room App What Are Business Applications? How to Choose a Virtual Data Room How to Plan a Data Room Review Coronavirus Guide What is a Virtual Data Room? What Is Data Science? What Is an Operating System? Turbotax Small Business Review How Online VDRs Are Used in M&A Deals Why Choose VDR Software? The Power of Business Software The Benefits of a Software Board Online Data Room Review The Importance of Tech Knowledge Improving Accuracy of Financial Data Online Business Records – How to Keep Your Online Business Records Accurate and Secure What is a Board Portal De? DealRoom Review – A Review of VDR Software M&A Due Diligence for Private Companies The Virtual Data Room Review Why Companies Use a Data Room Review to Facilitate M&A Transactions The Best File Sharing Services How Online VDRs Are Used in M&A Deals Best Virtual Data Room How to Choose a Best Board Room Provider Choosing a Data Room for Due Diligence What Is a Data Room Business Software? Best Data Room Providers Review Data Room Providers Review Mostbet Tr Resmî Web Sitesinde Giriş Ve Kayıt Olm Kumar Oynamak Için En Iyi Yerdir The Benefits of Cloud Data Services for Enterprises Online Data Room and SSL How to Build a Diverse Board of Directors Best Virtual Data Review A Data Room Service Review How Runn Makes Project Data Accessible, Accurate and Shareable Five Pillars of Information Protection The Importance of Online Business Reports Benefits of Colocation Services Virtual Data Rooms Guide Choosing a Business Virtual Data Room Choosing the Right VDR Service Review How to Conduct a Virtual Data Room Review

Investment

In high-stakes votes, FDA advisors say evidence doesn't back Philip Morris' claims

Written by finanster
on January 25, 2018
Leave a comment

Evidence doesn’t support Philip Morris International’s claims that its heat-not-burn tobacco product cuts the risk of tobacco-related diseases and is likely to switch adult cigarette smokers, regulatory advisors said.

PMI is seeking approval from the U.S. Food and Drug Administration to market its heat-not-burn tobacco product as less risky than cigarettes. PMI says it has found exclusively using iQOS significantly lowers users’ risk of harm than if they were to continue smoking cigarettes.

The committee disagreed.

Members voted unanimously (aside from one abstention) against PMI’s claim that its heat-not-burn tobacco product cuts the risk of tobacco-related diseases. The panel also rejected a claim that iQOS is less risky than continuing to smoke cigarettes in a 5-4 vote.

One claim the committee voted in favor of was that iQOS reduces the body’s exposure to harmful or potentially harmful chemicals. However, it voted against the idea that reductions in exposure are reasonably likely to translate to a measurable and substantial reduction in morbidity and or mortality.

PMI told the committee it expects to switch 6 million adult smokers to iQOS if the FDA allowed it to market the system as less risky than cigarettes. Members were skeptical.

The majority said the likelihood iQOS users switching completely to the device is low to medium.

One member pointed to price as a barrier. If approved, the heating device would cost $79 and the price of accompanying tobacco sticks would be comparable to a pack of cigarettes.

PMI has said using the iQOS system exclusively offers the greatest reduction in harm. The committee was not convinced that people would use iQOS alone. The bulk said the odds of people using it in conjunction with cigarettes are high to medium.

One concern with alternative nicotine products like e-cigarettes is that they attract people who have never smoked, including kids and teens. PMI has said that’s unlikely because iQOS uses actual tobacco, unlike e-cigarettes, which are available in fruity, sweet flavors. The committee’s thoughts on the matter were mixed.

The recommendations are non-binding, meaning the FDA does not have to follow them. PMI has another application under FDA review that would simply allow iQOS to be sold in the U.S., without the lower-risk claims.

Regardless of the panel’s views, the process could help PMI’s other application, said Marc Scheineson, a partner at Alston & Bird and a former associate commissioner for legislative affairs of the FDA.

Philip Morris shares were down nearly 3 percent on Thursday. Shares of Altria, which would receive sole distribution for iQOS in the U.S., if approved, were down 2 percent.

Source: Investment Cnbc
In high-stakes votes, FDA advisors say evidence doesn't back Philip Morris' claims

Comments are closed.